928853-86-5

4-MMPB is a selective inhibitor of 15-lipoxygenase, with an IC50 of 18 μM. 4-MMPB has IC50s of 19.5 μM and 19.1 μM for soybean 15-lipoxygenase (SLO) and human 15-lipoxygenase-1 (15-LOX-1), respectively. 4-MMPB has potential for the research of prostate cancer[1][2][3][4].

4-MMPB is a selective lipoxygenase 15-lipoxygenase inhibitor with IC50 value of 18 μM. The IC50 values of it against soybean 15-lipoxygenase (SLO) and human 15-lipoxygenase-1 (15-LOX-1) were 19.5 μM and 19.1 μM, respectively. It has potential for prostate cancer research.

Store at -20°C

[1] M Bakavoli, et al. Design and synthesis of pyrimido[4,5-b][1,4]benzothiazine derivatives, as potent 15-lipoxygenase inhibitors. Bioorg Med Chem. 2007 Mar 1;15(5):2120-6. DOI:10.1016/j.bmc.2006.12.022
[2] Mohsen Nikpour, et al. Synthesis of new series of pyrimido[4,5-b][1,4] benzothiazines as 15-lipoxygenase inhibitors and study of their inhibitory mechanism. 2013, 22(10), 5036-5043.
[3] Seyed Jamal Alavi, et al. A novel class of human 15-LOX-1 inhibitors based on 3-hydroxycoumarin. Chem Biol Drug Des. 2018 Jun;91(6):1125-1132. DOI:10.1111/cbdd.13174
[4] Saffiyeh Saboormaleki, et al. 7-Farnesyloxycoumarin Exerts Anti-cancer Effects on a Prostate Cancer Cell Line by 15-LOX-1 Inhibition. Arch Iran Med. 2018 Jun 1;21(6):251-259. PMID:29940744